These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Evans M; Rees A Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559 [TBL] [Abstract][Full Text] [Related]
8. Excessive expression of miR-1a by statin causes skeletal injury through targeting mitogen-activated protein kinase kinase kinase 1. Fu CN; Song JW; Song ZP; Wang QW; Bai WW; Guo T; Li P; Liu C; Wang SX; Dong B Aging (Albany NY); 2021 Apr; 13(8):11470-11490. PubMed ID: 33864447 [TBL] [Abstract][Full Text] [Related]
9. The role of mitochondria in statin-induced myopathy. Apostolopoulou M; Corsini A; Roden M Eur J Clin Invest; 2015 Jul; 45(7):745-54. PubMed ID: 25991405 [TBL] [Abstract][Full Text] [Related]
10. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Werner M; Sacher J; Hohenegger M Br J Pharmacol; 2004 Nov; 143(6):715-24. PubMed ID: 15289292 [TBL] [Abstract][Full Text] [Related]
11. Involvement of Monocarboxylate Transporter 4 Expression in Statin-Induced Cytotoxicity. Kikutani Y; Kobayashi M; Konishi T; Sasaki S; Narumi K; Furugen A; Takahashi N; Iseki K J Pharm Sci; 2016 Apr; 105(4):1544-9. PubMed ID: 26935883 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity. Gee RH; Spinks JN; Malia JM; Johnston JD; Plant NJ; Plant KE Toxicology; 2015 Mar; 329():40-8. PubMed ID: 25578243 [TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle cell MHC I expression: implications for statin-induced myopathy. Singh P; Kohr D; Kaps M; Blaes F Muscle Nerve; 2010 Feb; 41(2):179-84. PubMed ID: 19813190 [TBL] [Abstract][Full Text] [Related]
14. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. Sacher J; Weigl L; Werner M; Szegedi C; Hohenegger M J Pharmacol Exp Ther; 2005 Sep; 314(3):1032-41. PubMed ID: 15914674 [TBL] [Abstract][Full Text] [Related]
15. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Seachrist JL; Loi CM; Evans MG; Criswell KA; Rothwell CE Toxicol Sci; 2005 Dec; 88(2):551-61. PubMed ID: 16141437 [TBL] [Abstract][Full Text] [Related]
16. [Statins and mitochondria]. Broniarek I; Jarmuszkiewicz W Postepy Biochem; 2016; 62(2):77-84. PubMed ID: 28132458 [TBL] [Abstract][Full Text] [Related]
17. The cerivastatin withdrawal crisis: a "post-mortem" analysis. Maggini M; Raschetti R; Traversa G; Bianchi C; Caffari B; Da Cas R; Panei P Health Policy; 2004 Aug; 69(2):151-7. PubMed ID: 15212862 [TBL] [Abstract][Full Text] [Related]
18. A system to monitor statin-induced myopathy in individual engineered skeletal muscle myobundles. Zhang X; Hong S; Yen R; Kondash M; Fernandez CE; Truskey GA Lab Chip; 2018 Sep; 18(18):2787-2796. PubMed ID: 30112530 [TBL] [Abstract][Full Text] [Related]
20. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT; Staffa JA; Parks M; Green L Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]